Yonemoto Y - Search Results

1

Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13.

Sakane H, Okamura K, Inoue M, Inoue H, Yonemoto Y, Mitomi H, Tsuchida K, Suto T, Kaneko T, Chikuda H. Sakane H, et al. Among authors: yonemoto y. BMC Rheumatol. 2022 Dec 7;6(1):74. doi: 10.1186/s41927-022-00304-9. BMC Rheumatol. 2022. PMID: 36474258 Free PMC article.

2

Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis.

Okamura K, Yonemoto Y, Suto T, Okura C, Takagishi K. Okamura K, et al. Among authors: yonemoto y. Mod Rheumatol. 2015 Jul;25(4):534-9. doi: 10.3109/14397595.2014.998361. Epub 2015 Feb 11. Mod Rheumatol. 2015. PMID: 25529033 Clinical Trial.

3

Short-term daily teriparatide in patients with rheumatoid arthritis.

Kaneko T, Okamura K, Yonemoto Y, Okura C, Suto T, Tachibana M, Tamura Y, Inoue M, Chikuda H. Kaneko T, et al. Among authors: yonemoto y. Mod Rheumatol. 2018 May;28(3):468-473. doi: 10.1080/14397595.2017.1362093. Epub 2017 Aug 14. Mod Rheumatol. 2018. PMID: 28805099

4

The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.

Suto T, Yonemoto Y, Okamura K, Sakane H, Takeuchi K, Tamura Y, Kaneko T, Ayabe K, Chikuda H. Suto T, et al. Among authors: yonemoto y. Mod Rheumatol. 2019 Sep;29(5):775-781. doi: 10.1080/14397595.2018.1510879. Epub 2018 Dec 20. Mod Rheumatol. 2019. PMID: 30092680

5

The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT.

Okamura K, Yonemoto Y, Arisaka Y, Takeuchi K, Kobayashi T, Oriuchi N, Tsushima Y, Takagishi K. Okamura K, et al. Among authors: yonemoto y. Rheumatology (Oxford). 2012 Aug;51(8):1484-91. doi: 10.1093/rheumatology/kes064. Epub 2012 Apr 17. Rheumatology (Oxford). 2012. PMID: 22513145

6

Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.

Okamura K, Yonemoto Y, Okura C, Kobayashi T, Takagishi K. Okamura K, et al. Among authors: yonemoto y. Mod Rheumatol. 2015 Mar;25(2):235-40. doi: 10.3109/14397595.2014.938401. Epub 2014 Jul 28. Mod Rheumatol. 2015. PMID: 25065917

7

Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT.

Okamura K, Yonemoto Y, Okura C, Higuchi T, Tsushima Y, Takagishi K. Okamura K, et al. Among authors: yonemoto y. BMC Musculoskelet Disord. 2014 Nov 22;15:393. doi: 10.1186/1471-2474-15-393. BMC Musculoskelet Disord. 2014. PMID: 25417119 Free PMC article.

8

Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study.

Yonemoto Y, Okamura K, Takeuchi K, Ayabe K, Kaneko T, Matsushita M, Tamura Y, Iso T, Okura C, Otsuka K, Inoue H, Takagishi K. Yonemoto Y, et al. Mod Rheumatol. 2016;26(1):24-8. doi: 10.3109/14397595.2015.1069472. Epub 2015 Aug 3. Mod Rheumatol. 2016. PMID: 26140464

9

[18F]fluorodeoxyglucose uptake as a predictor of large joint destruction in patients with rheumatoid arthritis.

Yonemoto Y, Okamura K, Takeuchi K, Kaneko T, Kobayashi T, Okura C, Tsushima Y, Takagishi K. Yonemoto Y, et al. Rheumatol Int. 2016 Jan;36(1):109-15. doi: 10.1007/s00296-015-3331-0. Epub 2015 Aug 2. Rheumatol Int. 2016. PMID: 26232929

10

Prediction of Large Joint Destruction in Patients With Rheumatoid Arthritis Using 18F-FDG PET/CT and Disease Activity Score.

Suto T, Okamura K, Yonemoto Y, Okura C, Tsushima Y, Takagishi K. Suto T, et al. Among authors: yonemoto y. Medicine (Baltimore). 2016 Feb;95(7):e2841. doi: 10.1097/MD.0000000000002841. Medicine (Baltimore). 2016. PMID: 26886646 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters